Stay updated on Nivolumab Plus Bevacizumab in GBM Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Bevacizumab in GBM Clinical Trial page.

Latest updates to the Nivolumab Plus Bevacizumab in GBM Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe ClinicalTrials.gov record for the nivolumab and bevacizumab glioblastoma study is available, including its treatment arms, eligibility criteria, outcomes, locations, and study documents. The prior error page and temporary NIH announcement are no longer shown.SummaryDifference71%

- Check21 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check28 days agoChange DetectedA sitewide NIH notice about updates to terminology appears above the study record page, which still displays a 403 error.SummaryDifference1%

- Check35 days agoChange DetectedThe footer’s site revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1, while the study page remains a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the previously visible study details with an access restriction notice. This appears to be an access issue rather than a substantive update to the page content.SummaryDifference0.5%

Stay in the know with updates to Nivolumab Plus Bevacizumab in GBM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Bevacizumab in GBM Clinical Trial page.